Vocanz 40mg (10 tablets/box)

Indications

Indicated for the chronic management of hyperuricemia in patients with gout. Not recommended for the treatment of asymptomatic hyperuricemia.

Contraindications

Know hypersensitive to any ingredient in the formulation.

Concomitant therapy with azathioprine, mercaptopurine, or theophylline.

Compositon/Ingredients

Dosage and administration

The management of hyperuricemia in patients with gout: initial dosage of 40 mg once daily, if do not achieve serum urate concentrations < 6 mg/dL: increased to 80 mg once daily.

Precaution

A risk of cardiovascular thromboembolic events.

Causality cannot be excluded, do not restart febuxostat if liver injury is confirmed and no alternate etiology can be found.

Serious allergic/hypersensitivity reactions: febuxostat should be immediately stopped. If reactions have been developed (including Stevens-Johnson syndrome and acute anaphylactic reaction/shock): febuxostat must not be restarted.

Patients with rare hereditary problems of galactose intolerance, total lactase deficiency or glucose-galactose malabsorption should not take this medicine.

Pregnancy: justify the potential benefit/potential risk. Nursing woman.

Driving/using machinery.

Safety and efficacy have not been established in pediatric patients < 18 years of age.

Storage

Store at temperature below 30°C, protect from light.